Zacks downgrades Inovio Pharmaceuticals stock to Hold with USD 3.17 consensus target

Published on 10/20/2026 at 18:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Zacks cut Inovio to Hold on October 14, 2026. Inovio Pharmaceuticals stock costs EUR 0.89 on October 20, 2026 at Lang & Schwarz.

Analyst rating and regulatory date

Zacks downgraded Inovio Pharmaceuticals to Hold in a report covered by MarketBeat on October 14, 2026, while the consensus target stood at USD 3.17.
The Food and Drug Administration set October 30, 2026 as the target action date for INO-3107.
Inovio Pharmaceuticals stock costs EUR 0.89 at Lang & Schwarz on October 20, 2026 at 6:44 p.m. CEST.
Yahoo Finance listed an estimated earnings date of November 10, 2026.

INO, US45773H4092, Illustration mit AI erstellt.

Inovio Pharmaceuticals (ISIN US45773H4092) became the subject of a Zacks Research downgrade to Hold, while the consensus target remained USD 3.17, as MarketBeat reported on October 14, 2026. The stock was trading at EUR 0.89 at Lang & Schwarz on October 20, 2026 at 6:44 p.m. CEST.

October 30 is the key date

Inovio is approaching the target action date for INO-3107, its lead candidate for recurrent respiratory papillomatosis. The company described the candidate and its regulatory program on its investor-relations site. The Food and Drug Administration target date is October 30, 2026, according to the Q2 2026 earnings-call material indexed by Yahoo Finance.

What does the rating mean?

The rating change contrasts with the USD 3.17 average target reported for eight research firms. MarketBeat also said the quarterly loss was USD 0.07 per share in the second quarter of 2026, versus a consensus loss of USD 0.22 per share, a USD 0.15 difference.

Nasdaq range remains wide

Inovio stock was quoted at USD 1.01 on the Nasdaq on October 20, 2026 at 12:54 p.m. ET, with the exchange session open. The 52-week range was USD 0.56 to USD 2.72, placing the current Nasdaq quote USD 1.71 below the high and USD 0.45 above the low.

The company remains a biotechnology developer focused on DNA medicines, including INO-3107 and its CELLECTRA delivery technology. Yahoo Finance listed biotechnology as the industry and showed an estimated earnings date of November 10, 2026, in its company profile.

Dates and valuation signals

The October 30 regulatory decision is the nearer event, followed by the estimated November 10 earnings date. The contrast between the USD 3.17 consensus target and the USD 1.01 Nasdaq quote highlights how heavily the valuation depends on regulatory progress rather than current operating earnings.

Comparison with peers

Moderna: up 4.97 percent on October 20, 2026, P/E minus 29.97, market capitalization USD 95.1 billion. Sarepta Therapeutics: up 7.67 percent on October 20, 2026, P/E minus 6.58, market capitalization USD 2.0 billion.

Stock keeps regulatory focus

For investors, October 30 is the next concrete decision point, while the latest rating change gives the market a more cautious analyst signal. The Nasdaq quote and the EUR price point to a highly volatile biotechnology listing with a wide annual trading range. The further course of trading is shown by the continuously updated real-time quote of Inovio Pharmaceuticals stock.